secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alzamend Neuro, Inc. (ALZN)
CIK:        0001677077
Form:       8-K
Filed at:   2023-06-22T23:59:59+00:00
Accession:  0001214659-23-008740
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alzamend Neuro announces positive Phase IIA results for AL001; identifies MTD without need for lithium TDM
--------------------------------------------------------------------------------

- Phase IIA multiple ascending dose study identified MTD of lithium carbonate equivalent 240 mg TID, unlikely to require lithium TDM.
- Company plans two Phase II trials for mild-to-moderate Alzheimer's, initiated by Q1 2024.
- Plans to file INDs for bipolar disorder, major depressive disorder, and PTSD by end of 2023.
- CEO states data supports AL001 as next-gen lithium therapy without TDM.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1677077/000121465923008740/0001214659-23-008740-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1677077/000121465923008740/z6212308k.htm
  HTML page:      https://secwatch.observer/filing/0001214659-23-008740

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer